3Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature, 2001, 409: 307-312.
4Ghosh S, Singh AK, Anma B, et al. The genomic organization of mouse rcsistin reveals major differences from the human resistin: functional implications. Gone, 2003, 305: 27-34.
5Lee SH, Ha JW, Kim JS, et al. Plasma adiponvctin and resistin levels as predictors of mortality in patients with acute myocardial infarction: data from infarction prognosis study registry. Coron Artery Dis, 2009, 20: 33-39.
6Lazo M, Clark JM. The cpidcmiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis, 2008, 28: 339-350.
7Tarquini R, Lazzeri C, Boddi M, et al. Non-alcoholic fatty liver disease: a new challenge for cardiologists. G Ital Cardiol (Rome), 2010, 11: 660-669.
8Gomez-Lechon MJ, Donato MT, Martinez-Romero A, et al. A human hepatocellular in vitro model to investigate steatosis. Chem Biol Interact, 2007, 165:106-116.
9Wang D, Wei Y, Pagliassotti MJ. Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology, 2006, 147:943-951.
10Curat CA, Wegner V, Sengenes C, et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia, 2006, 49: 744-747.
